News & Events

FlowAid opens enrollment for a new clinical trial of its FlowAid FA100 SCCD in the New York Tri-State area

FlowAid Medical Technologies Inc. is pleased to announce the opening of enrollment in a clinical trial of its FlowAid FA100 SCCD in the New York Tri-State area. If you suffer from Painful Diabetic Peripheral Neuropathy (DPN), are interested in learning more and participating in this study, please contact us at

The FA100 device is a portable noninvasive electric muscle pump. The device is meant for daily home use, and does not interfere with any activities or schedule. The trial will last one month and requires an introductory visit, as well as one closing visit, with the principal investigators.

No medications are being evaluated as part of this study.

To find out more information about the device or read some of the published Medical Journal articles written about the device, please visit or

The use of FlowAid FA100, a novel device, for management of DFUs and ischaemic pain, evidenced by a series of case studies – by Graham Bowen, Podiatry Clinical Lead, Solent NHS Trust, Southampton

Poster_Presentation_for_Wounds UK 2017 See the poster presented by Graham Bowen at the Wounds UK Annual Conference November 5-7, 2017 at Harrogate

Methods: 8 patients, 7 with type 2 and 1 with type 1 diabetes were selected, HbA1c range from 65-112 mmol/mol, who presented with a range of DFUs (neuropathic and ischaemic). Each patient was advised to use the FlowAid FA 100 device for a period of 4-6 weeks, and to use the device 2 twice a day for a period of 1-2 hours. At each Podiatry appointments, DFUs were assessed as per standard care. Each patient was asked to keep a pain diary, by means of a Visual analogue scale (VAS), record any positive or negative experiences and describe any improvements in their quality of life as a result of using FlowAid100.

Results: All 8 completed the evaluation with two extending the evaluation period by a further 4 weeks, with one extending to 3 months; 2 ischaemic patients reported a reducing in their VAS pain score from 8 to 5. 2 patients reported a return of sensation in neuropathy and clinically, improvements were noted in wound bed presentation and wound size reduction in all patients selected

One patient 50 years with type 2 diabetes who presented with a significant chronic >12 months heel DFU (SINBAD score of 5) made significant progress to full resolution after staring using FlowAid FA100 in conjunction with other treatment options. This prevented this patient from being admitted / progressing on to elective amputation. The edge of the wound once FlowAid FA 100 was activated, showed an increase in perfusion and the patient reported his foot feeling warmer.

FlowAid FA100 has a place in the management and prevention of diabetic foot disease. During the vascular assessment of the 8 patients in the evaluation, as soon as the device was activated, there was a significant audible improvement in Doppler sound in all the pedal pulses.

Next Steps:
A larger scale study is indicated to look at the cost benefits of the FlowAid FA100 for a greater range of DFUs. Wider Implications for use of this device would be in those groups of patients identified at Moderate and High Risk (NICE 2016) as the long term benefits of using the device in improving circulation may well yield both significant financial savings in the long term for this group of patients in the management of impaired vascular and neuropathy in the diabetic foot.

FlowAid discussed in talk on New Technology in “Diabetic Foot Ulceration – New Treatment Strategies” by Graham Bowen, Clinical Lead for Podiatry, Solent NHS Trust

May 18, 2017 Primary Care & Public Health Conference NEC Birmingham, UK
(discussed in thread

Graham Bowen’s presentation was from 11:10 to 11:40, part of the
Podiatry and Orthotics Programme

The portion of the presentation about the FlowAid FA100 SCCD follows
NEC Presentation May 2017 V4.1

New Case Study – Recently Published

Sequential Contraction Compression Device Aids in the Healing of an Ischemic Foot Ulceration in a Chronic Dialysis Patient: A Case Report – J Rosenblum
Published in Journal of Clinical and Medical Case Studies 2017:2 39-41

from the case study:

“The FlowAid FA-100 SCCD produces the same effect as the ICD without the complications mentioned above. The SCCD is small, portable and easy to use. Patient compliance is extremely high. The resulting contractions of the leg help to evacuate the limb of pooled venous blood and allows for more and better arterial return thus revascularizing the limb and causing an increase
in tissue oxygenation.

While not intended as a primary wound care device, the clinical results generated by the SCCD imply that it would be a useful adjunct therapy in wound care, especially in increasing the vasculature to the foot and leg. A clinical trial proving this is called for, but clinical practice would indicate that the SCCD has a place in the wound care field as well as the vascular”

JCMCS-2-39 (1)

US Food and Drug Administration FDA clearance

FlowAid has received U.S. Food and Drug Administration FDA clearance for its FA100 SCCD (Sequential Continuous Contraction Device) for the following indications: increase of local blood circulation, immediate post-surgical stimulation of calf muscles to prevent venous thrombosis, prevention or retardation of disuse atrophy and edema reduction. The FA100 SCCD is the first device of its kind cleared by the FDA for the indication of edema reduction.

Additional FDA applications will be submitted to expand our claims for other disease-specific indications, including the treatment of Diabetic Peripheral Neuropathy and Lymphedema.




Positive Results from a Study of Patients with Diabetic Peripheral Neuropathy

A New Look at a Therapeutic Treatment for Diabetic Peripheral Neuropathy (DPN)

segments from the Press Release:
FlowAid Medical Technologies Corp. announced positive results from a study of the usage of its FA100 Sequential Contraction Compression Device among a group of patients with diabetic peripheral neuropathy. Following 30 days of supervised home use, the patients reported significantly less pain, less reliance on analgesics and fewer nights of disturbed sleep.

FlowAid CEO Jacob Brezel: “The new research could alter the way Diabetic Neuropathy is understood and treated. Use of the FA100 SCCD on patients suffering from hypoesthetic DPN restores sensation. We are planning larger studies that will bear out our findings”

Based on the study “Sequential Contraction Compression Device Therapy affects Symptomatic Diabetic Peripheral Neuropathy”, published in the Journal of Diabetic Complications & Medicine accessible on our Clinical webpage

Health Canada Medical Device License Issued

The Health Canada Medical Device License was issued on 18 August 2016 for the FA100 SCCD just four weeks after receiving the European Union CE Mark

UK – Multi-center Study Using the FA100 SCCD

A multi-center study using the FA100 SCCD has started in several major NHS hospitals and clinics in Southampton, UK and in Portsmouth, UK.


Dr Graham Bowen, Head of Podiatry & Clinical Services Manager at Solent NHS Trust trying out the FA100 SCCD with CEO Jacob Brezel

Dr Graham Bowen, Head of Podiatry & Clinical Services Manager at Solent NHS Trust trying out the FA100 SCCD with CEO Jacob Brezel


In other UK news:

John Bell & Croyden Pharmacists and online store have expressed strong interest in the FA100 SCCD and said they want it on their shelf. The history of John Bell & Croyden goes back to the beginning of the pharmacist profession in the United Kingdom. They hold accreditation of Royal Warrant as Pharmacists to Her Majesty Queen Elizabeth II. Product will be available by early September.

CE Mark & ISO Certification for FlowAid FA100 SCCD

We are happy to announce that we received the CE Mark for the FA100 SCCD in Europe. We also received ISO 13485 certification for our Quality Management System (QMS) in accordance with EU requirements and the Canadian Medical Device Conformity Assessment System (CMDCAS).
Click here to view certifications

UAE – Multi-center Study Using the FA100 SCCD

Evaluations of the FA100 SCCD are in process by a diabetologist in a Private Hospital in Sharjah, by a vascular surgery team in Dubai Hospital, and by a podiatrist at The Dubai Diabetes Center.

India – Study Using the FA100 SCCD

Another study will be taking place at the Kerala Institute of Medical Science (KIM) in Anayara, Thiruvananthapuram District, Kerala, India.

Singapore – Multi-center Study Using the FA100 SCCD

Dr.  Jonathan Rosenblum, of our Scientific Advisory Board, met with heads of departments, surgeons and clinicians in Singapore General Hospital, Tan Tock Seng Hospital, Changi General Hospital, National University Hospital and St. Luke’s Hospital.

Overwhelming interest in the FlowAid FA100 SCCD at the FIP World Congress of Podiatry in Montreal

We presented our device before a large audience at the FIP World Congress of Podiatry in Montreal on May 26th 2016. There was overwhelming interest in the FlowAid FA100 SCCD. “A Technology for Treating Circulatory Disorders of the Lower Extremities” was presented by Dr Jonathan Rosenblum. Watch his presentation below:

We are pleased to announce the new additions to our Scientific Advisory Board:

Prof. Marco Romanelli is a Board certified, Consultant Dermatologist at the Department of Dermatology, University of Pisa, Italy

Prof. Luc Téot is Associate Professor of Plastic Surgery in Wound Healing and Burns at Montpellier University Hospital France

Dr. Michael S. Miller is the Assistant Professor of Surgery Des Moines University Osteopathic Medical Center Des Moines, IA.  Dr. Miller is the Medical Director at The Wound Healing Centers Bedford, IN: Linton, IN: Terre Haute, in USA.

Dr. Jeremy Tamir MD is the Director of the Wound Care Center, and Plastic Surgery Clinic of Halstead Hospital Kansas, USA.

Dr. Jonathan Rosenblum serves as an Adjunct Clinical Instructor at the Dept. of Medicine in NY College of Podiatric Medicine, New York USA

Page 1 of 11